

# Phase 1 clinical development of anti-cancer bispecific antibody ABL501 targeting LAG-3 and PD-L1



ONCOLOGY	Phase 1
Product Type	Bispecific antibody
Indication	Solid tumors including Melanoma, Non-small cell lung cancer, Colorectal cancer, Ovarian cancer, Kidney cancer, etc.
Target	LAG-3, PD-L1
MoA(Mechanism of Action)	Dual inhibition of LAG-3/MHC-II and PD-L1/PD-1 interaction
Competitiveness	Bridges dendritic cell and T cells through binding to LAG-3 and PD-L1, leading to dendritic cell activation and cross-activation of CD8+ T cells in close vicinity Potentiates tumor killing by anchoring CD8+ T cells to PD-L1 expressing tumors
Development Stage	Phase 1
Route of Administration	Intravenous